Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations.

Mazieres J, Cropet C, Montané L, Barlesi F, Souquet PJ, Quantin X, Dubos-Arvis C, Otto J, Favier L, Avrillon V, Cadranel J, Moro-Sibilot D, Monnet I, Westeel V, Le Treut J, Brain E, Trédaniel J, Jaffro M, Collot S, Ferretti GR, Tiffon C, Mahier-Ait Oukhatar C, Blay JY.

Ann Oncol. 2020 Feb;31(2):289-294. doi: 10.1016/j.annonc.2019.10.022. Epub 2020 Jan 3.

2.

Management of pulmonary toxicity associated with immune checkpoint inhibitors.

Delaunay M, Prévot G, Collot S, Guilleminault L, Didier A, Mazières J.

Eur Respir Rev. 2019 Nov 6;28(154). pii: 190012. doi: 10.1183/16000617.0012-2019. Print 2019 Dec 31. Review.

3.

[Sarcoid-like granulomatosis in cancer patients treated with immune checkpoints inhibitors].

Faviez G, Bousquet E, Rabeau A, Rouquette I, Collot S, Goumarre C, Meyer N, Prevot G, Mazieres J.

Rev Mal Respir. 2018 Nov;35(9):963-967. doi: 10.1016/j.rmr.2018.08.003. Epub 2018 Sep 13. French.

PMID:
30220489
4.

[Toxicity of immune checkpoints inhibitors].

Delaunay M, Caron P, Sibaud V, Godillot C, Collot S, Milia J, Prévot G, Mazières J.

Rev Mal Respir. 2018 Dec;35(10):1028-1038. doi: 10.1016/j.rmr.2017.08.006. Epub 2018 Sep 10. Review. French.

PMID:
30213624
5.

Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients.

Delaunay M, Cadranel J, Lusque A, Meyer N, Gounant V, Moro-Sibilot D, Michot JM, Raimbourg J, Girard N, Guisier F, Planchard D, Metivier AC, Tomasini P, Dansin E, Pérol M, Campana M, Gautschi O, Früh M, Fumet JD, Audigier-Valette C, Couraud S, Dalle S, Leccia MT, Jaffro M, Collot S, Prévot G, Milia J, Mazieres J.

Eur Respir J. 2017 Aug 10;50(2). pii: 1700050. doi: 10.1183/13993003.00050-2017. Print 2017 Aug. Erratum in: Eur Respir J. 2017 Nov 9;50(5):.

6.

Hemostastic embolization in oncology.

Revel-Mouroz P, Mokrane FZ, Collot S, Chabbert V, Rousseau H, Meyrignac O, Otal P.

Diagn Interv Imaging. 2015 Jul-Aug;96(7-8):807-21. doi: 10.1016/j.diii.2015.06.008. Epub 2015 Jul 15. Review.

7.

Active human herpesvirus 6 infection in a patient with drug rash with eosinophilia and systemic symptoms.

Descamps V, Collot S, Mahé E, Houhou N, Crickx B, Ranger-Rogez S.

J Invest Dermatol. 2003 Jul;121(1):215-6. No abstract available.

8.

Human herpesvirus-6 encephalitis associated with hypersensitivity syndrome.

Descamps V, Collot S, Houhou N, Ranger-Rogez S.

Ann Neurol. 2003 Feb;53(2):280. No abstract available.

PMID:
12557304
9.

Real-time PCR for quantification of human herpesvirus 6 DNA from lymph nodes and saliva.

Collot S, Petit B, Bordessoule D, Alain S, Touati M, Denis F, Ranger-Rogez S.

J Clin Microbiol. 2002 Jul;40(7):2445-51.

Supplemental Content

Loading ...
Support Center